Tag: pharmaceuticals

  • Trial of Insulin-Coated Gold Nanoparticles Approved

    Midatech Ltd. in Oxford, U.K. says it has received approval from regulatory authorities in Switzerland for a clinical trial of the company’s insulin-coated gold nanoparticles. The company says it is the first test in humans of therapies based on solid nanoparticles. Midatech says the trial will test the safety of insulin-coated gold nanoparticles when applied…

  • Geron Halts Embryonic Stem Cell Research, Clinical Trial

    Geron Corporation, a biotechnology company in Menlo Park, California, says it has discontinued its development of therapies based on human embryonic stem cells to focus on cancer drugs. The immediate results of its decision are to end a clinical trial of its stem cell drug on patients with spinal cord injuries — the first clinical…

  • FDA Funds Evaluation of Pain Drug Clinical Trial Methods

    The Food and Drug Administration is funding a study by researchers at University of Rochester in New York and University of Washington in Seattle to find different ways of evaluating drugs designed to relieve acute and chronic pain. The grant of up to $4.5 million over five years aims to better understand why few new…

  • Full Coverage of Meds Reduces Later Heart Attacks, Failures

    Academic and industry researchers have found heart attack patients whose insurance fully covered their medications had lower rates of rehospitalization for heart attack or heart failure compared to patients who had prescription co-pays. The team from Brigham and Women’s Hospital and Harvard Medical School in Boston, Aetna Insurance in Hartford, Connecticut, and CVS Caremark in…

  • Protein Discovered That Enables Heart Tissue Repair

    Researchers at the Max Planck Institute for Heart and Lung Research in Bad Nauheim, Germany have found a protein that stimulates regression of individual heart muscle cells into their precursor cells, a step required for self-generated healing of damaged heart tissue. The Max Planck Institute, with colleagues from the Schüchtermann Klinik in Bad Rothenfelde, published…

  • Intentional Poisonings Result in 14K+ Emergency Room Visits

    A study by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows intentional poisonings — purposeful attempts to drug other people without their knowledge — resulted in 14,720 hospital emergency room visits in 2009. The report by SAMHSA, an agency of the Department of Health and Human Services, indicates most victims were female (63%)…

  • GSK to Fund Canadian Life Sciences Start-Ups, Institutes

    The global pharmaceutical company GlaxoSmithKline Inc. (GSK) announced in Toronto a new $50 million fund for early stage life sciences research in Canada. GSK says the Canada Life Sciences Innovation Fund will identify investment opportunities at Canada’s academic and health institutions, translational research centers, and start-up companies. Paul Lucas, president of GlaxoSmithKline Canada, calls the…

  • University Spin-Off Lands Radiation Countermeasure Contract

    RxBio Inc., an early stage biotech company spun off from the University of Tennessee Health Science Center (UTHSC) in Memphis, has received a contract from Biomedical Advanced Research and Development Authority for the company’s radiation countermeasure drug. The contract has a potential value of $24 million over the next two years. The contract, with a…

  • Depression Drug Fails in First Phase 3 Trial

    A drug candidate designed to treat major depressive disorder has not met its success targets in the first round of phase 3 clinical trials. The drug, TC-5214 (S-mecamylamine), is made by global pharmaceutical company AstraZeneca and Targacept Inc., biotechnology company in Winston-Salem, North Carolina. The clinical trial tested TC-5214 as a therapy for major depressive…

  • ACADIA, Meiji Seika Advance Schizophrenia Drug to Trials

    ACADIA Pharmaceuticals, a biotechnology company in San Diego, says its drug AM-831 developed with Meiji Seika Pharma Co. Ltd. in Japan to treat schizophrenia has received clearance from the Food and Drug Administration to begin phase 1 clinical trials. The clinical study will test the drug’s safety, tolerability, and interaction with the body. AM-831 was…